Fundraising Fox
Ascendis Pharma A/S
operating company · company profileHellerup · 15 people tracked
Find your way into Ascendis Pharma A/S
Sign up to see every warm intro you have to Ascendis Pharma A/S
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ascendis Pharma A/S team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Ascendis Pharma employs an innovation algorithm to identify unmet medical needs where clinically validated parent drugs align with its TransCon technology platform. The company focuses on building a pipeline of therapeutic candidates primarily in endocrinology rare diseases and oncology, aiming to create therapies that meaningfully improve patient outcomes.
Source: firm website, verified Sep 27, 2026.
Team · 15 people
from the firm's website & public directories
Founder of Ascendis Pharma in 2007 and its President and CEO. Previously led LifeCycle Pharma, headed Maxygen's Pharmaceutical Division, co-founded ProFound Pharma, and held senior roles at Novo Nordisk.
EVP and Chief Medical Officer since November 2024, leading clinical development and medical affairs. A practicing endocrinologist at Stanford University Health Care.
Board member since 2022 and Executive Chairman of Respira Therapeutics. Previously held commercial and operating roles at MyoKardia, ChemoCentryx, and Actelion Pharmaceuticals.
EVP of Product Supply and Quality, having led the function since 2015. Previously at NNE Pharmaplan and ALK-Abelló.
EVP and President of Ascendis US since January 2025, leading the US organization. Previously spent 13 years at Genentech, most recently as VP and Head of Rare Diseases.
Board member and former longtime CEO and Chair of BioMarin Pharmaceutical. Previously led Genencor and SangStat Medical Corporation.
Chief Regulatory & Safety Officer since November 2024, heading Global Regulatory Affairs & Pharmacovigilance. Formerly held regulatory leadership roles at Alexion/AstraZeneca and Horizon Therapeutics.
EVP and Head of Research & Product Development, with the company since 2007. Holds a Ph.D. in Natural Products Chemistry from the University of Copenhagen.
Board member since 2018. Former partner and Denmark chairman at PricewaterhouseCoopers, with expertise auditing listed pharmaceutical and biotech companies.
Board member since 2017. Former President International at Intercept Pharmaceuticals, with earlier leadership roles at Gilead Sciences and GlaxoSmithKline.
EVP and Chief Administration Officer since 2007 and Managing Director of Ascendis Pharma GmbH. Previously held HR and finance roles at LifeCycle Pharma and Acadia Pharmaceuticals.
EVP and Chief Legal Officer since January 2023, with the company since 2013. Former Ascendis board chairman and acting CFO; previously held finance and legal roles at Ørsted, LifeCycle Pharma, and Genmab.
EVP and CFO since January 2023, with the company since 2016. Previously led healthcare investment banking at Wedbush Securities and was a director at Merrill Lynch.
Chief Business Officer since September 2024, overseeing business development, global marketing, and commercial operations. Previously SVP of Enterprise Strategy at Bristol Myers Squibb.
Board member since 2022 and Head of Global Strategy, Business Development, Shared Value & Sustainability at Chiesi. Previously held corporate strategy roles at Servier and Ipsen.
Frequently asked questions
- What sectors does Ascendis Pharma A/S focus on?
- Ascendis Pharma A/S focuses on Biotech.
- Where is Ascendis Pharma A/S located?
- Ascendis Pharma A/S is headquartered in Hellerup, DK.
Images
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.